HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kratom In Supplements Reaches Dead End On DEA Direct Regulatory Path

This article was originally published in The Rose Sheet

Executive Summary

DEA says more kratom was seized from US firms in the first half of 2016 than in any previous year, but the seizures came two years after FDA imposed an import alert to stop shipments and three years after the agency stumbled out of the gate in determining whether the ingredient could be used in supplements.

You may also be interested in...



US HHS Pulled Recommendation To Make Kratom A Controlled Substance, But Kept Mum On Change

HHS released to industry proponents Reps. Mark Pocan and Morgan Griffith the letter it submitted in 2018 notifying DEA that it was rescinding recommendation it made in 2017 to list kratom active ingredients mitragynine and 7-hydroxymitragynine under Schedule I of the CSA.

Controversy Brews With 'Inaccurate' Reports Linking Kratom To Deaths

American Kratom Association and independent researchers explain the ingredient's history of safe use in a media briefing. Medical examiners "have tried to pin on kratom" the recent deaths of men in Florida and New York, says trade group Chairman Dave Herman.

DEA Takes Comments On Kratom, But Keeps Eye On Scheduling

DEA will accept comments through Dec. 1 on its proposal to move the active materials in kratom into Schedule I under CSA to avoid an imminent hazard to public safety.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS108527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel